These data suggest that targeting of BCL2 may represent a promising therapeutic strategy in SLE, and animal models of SLE treated with ABT-737 showed encouraging results.492 Based on these pre-clinical data, venetoclax has recently been tested in a phase I study in 73 women with SLE (NCT01686555). Here, BCL2 is linked to systemic lupus erythematosus.